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Abstract: A2B5+ cells isolated from human glioblastomas exhibit cancer stem cell properties. The 
A2B5 epitope belongs to the sialoganglioside family and is synthetized by the ST8 
alpha-N-acetyl-neuraminidase α-2,8-sialyltransferase 3 (ST8SIA3) enzyme. Glycolipids represent 
attractive targets for solid tumors; therefore, the aim of this study was to decipher A2B5 function in 
glioblastomas. To this end, we developed cell lines expressing various levels of A2B5 either by 
genetically manipulating ST8SIA3 or by using neuraminidase. The overexpression of ST8SIA3 in 
low-A2B5-expressing cells resulted in a dramatic increase of A2B5 immunoreactivity. ST8SIA3 
overexpression increased cell proliferation, migration, and clonogenicity in vitro and tumor growth 
when cells were intracranially grafted. Conversely, lentiviral ST8SIA3 inactivation in 
low-A2B5-expressing cells resulted in reduced proliferation, migration, and clonogenicity in vitro 
and extended mouse survival. Furthermore, in the shST8SIA3 cells, we found an active apoptotic 
phenotype. In high-A2B5-expressing cancer stem cells, lentiviral delivery of shST8SIA3 stopped 
cell growth. Neuraminidase treatment, which modifies the A2B5 epitope, impaired cell survival, 
proliferation, self-renewal, and migration. Our findings prove the crucial role of the A2B5 epitope 
in the promotion of proliferation, migration, clonogenicity, and tumorigenesis, pointing at A2B5 as 
an attractive therapeutic target for glioblastomas. 
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1. Introduction 
Glioblastomas (GBM) are the most malignant primary intracranial tumors in adults and are 
mainly characterized by necrosis, high proliferation, invasion, and neoangiogenesis [1]. 
Furthermore, GBM are composed of several cell types including tumor-initiating cells or cancer stem 
cells (CSCs), which are resistant to cell death and drive relapse. To increase treatment efficiency, 
targeting CSCs remains a major therapeutic challenge.  
Gangliosides are sialic-acid-containing glycosphingolipids that are most abundant in the 
nervous system. During brain development, the levels and patterns of gangliosides shift from simple 
gangliosides such as GM3 and GD3 to more complex ones such as GM1, GD1a, GD1b, and GT1B (for 
a review, see [2]). More than 20 years ago, some studies reported that in contrast to normal brain, 
gliomas express large amounts of GD2 and GD3 [3,4]. Moreover, treatment of glioma cells with the 
anti-ganglioside A2B5 monoclonal antibody reduced their migration in vitro [4]. It has been shown 
that GBM selectively express O-acetyl GD2 ganglioside [5]. More recently, the direct role of GD2 and 
GD3 expression in glioma invasion, motility, and tumor growth has been reported [6,7]. 
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A few years ago, we demonstrated in various glioma subtypes the presence of glial precursor 
cells expressing c-series gangliosides recognized by the A2B5 monoclonal antibody [8]. The A2B5 
monoclonal antibody, originally prepared against chicken embryo retina cells [9], mainly recognizes 
trisialoganglioside GT3 at the surface of the cells [10]. These antigens, widely expressed during early 
brain development [2,11], are also known to characterize a small fraction of human adult subcortical 
white matter cells that have stem cell properties [12]. Several ganglioside markers including SSEA3, 
SSEA4, GD2, and GD3 have been identified in GBM CSCs [13]. Moreover, we have shown that the 
A2B5 epitope is another GBM CSC surface marker. In GBM, A2B5+ cells are able to migrate, divide, 
and differentiate into oligodendroglial and type 1 and 2 astroglial cells [8]. In agreement with other 
studies, we showed that only A2B5+ cells and not A2B5- cells display a high proliferation index, 
have the potential to generate primary and secondary spheres, and to develop tumors after 
orthotopic injection in nude mice independently of CD133 [14-16]. 
Altogether, these studies point out that gangliosides represent attractive GBM therapeutic 
targets. Gangliosides expressed at the cell surface are key regulators of cell recognition and 
signaling. It is therefore not surprising that they play a pleiotropic role in development and cancer. 
Gangliosides function in two distinct modes: cis and trans [17]. In the cis mode, gangliosides 
associate laterally with other membrane molecules, including receptors and ion channels, to 
modulate their activities. As an example, it has been shown that the ganglioside GD2 enhanced 
proliferation of breast cancer cells through the constitutive activation of the c-MET receptor [18]. In 
the trans mode, gangliosides—which extend into the extracellular space—interact with 
complementary glycan-binding proteins, thereby modifying cell-cell or cell-extracellular matrix 
interactions. Of particular interest is the negative influence of cell surface sialosides on immune cell 
function by interacting with the immune-inhibitory sialic-acid-binding immunoglobulin-like lectin 
(Siglec) family (reviewed in [19,20]). Therefore, cell surface sialosides are exploited by tumors to 
evade both innate and adaptative immune destruction. 
The aim of this study was to uncover which properties are conferred to GBM tumor cells by the 
expression of the A2B5 epitope. To achieve this goal, we manipulated A2B5 expression by 
genetically modifying its synthesis. It is known that A2B5 results in the addition of a third sialic acid 
on its precursor GD3 by the golgian ganglioside-specific ST8 alpha-N-acetyl-neuraminide 
α-2,8-sialyltransferase 3 (ST8SIA3). We overexpressed or suppressed the ST8SIA3 enzyme in GBM 
cell lines with different basal levels of A2B5, then studied their proliferation, migration, and 
clonogenicity in vitro and tumorigenesis ability in vivo. Because shST8SIA3 delivery in 
A2B5-high-expressing cells prevents continuous cell growth, as an alternative we used 
neuraminidase (sialidase) to cleave the sialic acid residues in α-2,8 to down-regulate A2B5 
immunoreactivity. In these models we demonstrated that the A2B5 level is positively correlated 
with cell proliferation, migration, clonogenicity, and tumorigenicity. Therefore, the glycolipids 
recognized by the A2B5 antibody are attractive targets for GBM therapy. 
2. Results 
2.1. Expression of ST8SIA3 Drives A2B5 Immunoreactivity 
In order to verify whether ST8SIA3 expression drives the expression of antigens exhibiting 
A2B5 immunoreactivity, we first used GBM cell lines expressing mild (U251-MG, 50.25% ± 3.06%) 
and low (U87-MG, 17.5% ± 0.96%) levels of A2B5 immunoreactivity. The ST8SIA3 gene was stably 
overexpressed by lentiviral infection or silenced by using shRNA technology in these two cell lines. 
Manipulated cell lines were analyzed by Western blot for ST8SIA3 and ST8SIA3-GFP expression 
(Figure 1A,B). ST8SIA3 mRNA was significantly increased in ST8SIA3-overexpressing cells 
(U251-ST8SIA3: 2239 ± 466 A.U.; U87-ST8SIA3: 9064 ± 2908 A.U., % of control RNA) when compared 
to shcontrol cell lines (U251-shcontrol: 51.12 ± 2.2 A.U., p < 0.05; U87-shcontrol: 0.2 ± 0.01 A.U., p < 
0.05) and to the shST8SIA3 cells (U251-shST8SIA3: 11.12 ± 1.1, p < 0.05; U87-shST8SIA3: 0.07 ± 0.01, p 
< 0.05) (Figure 1C,F). At the protein level, ST8SIA3 was increased in the ST8SIA3-overexpressing 
cells and decreased in the shST8SIA3 cells (Figure 1E,H). A2B5 quantification by flow cytometry 
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revealed a highly significant increase of A2B5 immunoreactivity in ST8SIA3-overexpressing cells as 
compared to the control cell line (U251-ST8SIA3: 85.13% ± 2.59%, p < 0.01; U87-ST8SIA3: 82.62% ± 
1.86%, p < 0.01) and a drastic reduction of A2B5-positive cells in shST8SIA3 cells (U251-shST8SIA3: 
2.7% ± 1.1%, p < 0.01; U87-shST8SIA3: 1.6% ± 0.2%, p < 0.01) (Figure 1D,G). By immunofluorescence, 
A2B5 was clearly highlighted when ST8SIA3 was overexpressed and abolished in U251-shST8SIA3 
and U87-shST8SIA3 (Figure 1E,H). Therefore, ST8SIA3 drives A2B5 immunoreactivity in GBM cells. 
 
 
Figure 1. Expression of ST8 alpha-N-acetyl-neuraminidase α-2,8-sialyltransferase 3 (ST8SIA3) drives 
A2B5 immunoreactivity. (A) Western blot analysis of ST8SIA3-GFP (72 KDa) and endogenous 
ST8SIA3 (45 KDa) in U251-MG, U251-shcontrol, U251-shST8SIA3 [D], and U251-ST8SIA3 cell lines. 
The expression level of β-actin (44 KDa) was used as a loading control. Ratios of ST8SIA3/β-actin 
relative to U251-shcontrol from 3 independent experiments are presented under the blot. (B) Western 
blot analysis of ST8SIA3-GFP and endogenous ST8SIA3 in U87-MG, U87-shcontrol, U87-shST8SIA3 
[B], and U87-ST8SIA3 cell lines. The expression level of β-actin was used as a loading control. Ratios 
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of ST8SIA3/β-actin relative to U87-shcontrol from 3 independent experiments are presented under 
the blot. (C) RT-qPCR demonstration of ST8SIA3 overexpression in the U251-ST8SIA3 cell line after 
lentiviral infection and comparison with U251-shcontrol and U251-shST8SIA3 [D] cell lines. Data 
from five independent experiments are expressed as mean ± SEM. (D) Flow cytometry analysis of 
A2B5 in the U251-ST8SIA3 cell line and comparison with U251-shcontrol and U251-shST8SIA3 [D] 
cell lines. Data from six independent analyses are expressed as mean ± SEM. (E) Immunofluorescence 
staining of ST8SIA3 (green) and A2B5 (red) in U251-ST8SIA3, U251-shcontrol, and U251-shST8SIA3 
[D] cell lines. Hoechst staining of the cell nuclei (blue) is also shown. Scale bar = 50 μm. (F) RT-qPCR 
demonstration of ST8SIA3 overexpression in the U87-ST8SIA3 cell line after lentiviral infection and 
comparison with U87-shcontrol and U87-shST8SIA3 [B] cell lines. (G) Flow cytometry analysis of 
A2B5 in the U87-ST8SIA3 cell line and comparison with U87-shcontrol and U87-shST8SIA3 [D] cell 
lines. (H) Immunofluorescence staining of ST8SIA3 (green) and A2B5 (red) in U87-ST8SIA3, 
U87-shcontrol, and U87-shST8SIA3 [B] cell lines. Cell nuclei are in blue. Scale bar = 50 μm. 
Non-parametric Wilcoxon-Mann-Whitney test shows * p < 0.05 and ** p < 0.01. 
2.2. Overexpression and Silencing of ST8SIA3 in Mild- and Low-A2B5-Expressing Cells Modulate Cell 
Death, Cell Proliferation, and Migration in GBM in Vitro 
We first quantified the impact of ST8SIA3 expression on cell viability. ST8SIA3 overexpression 
significantly increased cell viability over time as compared to shcontrol cells (U251-ST8SIA3, p < 0.01; 
U87-ST8SIA3, p < 0.01). However, no variation was recorded between shST8SIA3 cells and shcontrol 
cells (Figure 2A,F). DNA fragmentation (sub/G1) analyses showed a decrease of cell death in 
ST8SIA3-overexpressing cells as compared to control cells and, to the contrary, a significant increase 
of cell death in shST8SIA3 cell lines (Figure 2B,G). Ki67 immunofluorescence showed that cells 
overexpressing ST8SIA3 proliferated more than the control cells, and inversely, the shST8SIA3 cells 
proliferated less than the control cells (Figure 2C,H). We then analyzed the effect of ST8SIA3 
expression on cell migration. The overexpression of ST8SIA3 significantly boosted the migration 
ability of the cells as compared to shcontrol cells (U251-ST8SIA3, p < 0.01; U87-ST8SIA3, p < 0.01). 
Conversely, the silencing of ST8SIA3 abrogated migration ability (U251-shST8SIA3, p < 0.001; 
U87-shST8SIA3, p < 0.001; Figure 2D,E,I,J). Altogether our results show that A2B5 immunoreactivity 
is positively correlated with cell viability, proliferation, and migration in GBM cell lines. 
2.3. ST8SIA3 Overexpression in Low-A2B5-Expressing Cells Increases Clonogenicity and Tumorigenicity 
By limiting dilution assay in serum-free medium, the U87-ST8SIA3 cells exhibited higher 
clonogenicity than U87-shcontrol and U87-shST8SIA3 (76% versus 68% versus 52%) (Figure 3A). 
These differences were statistically significant between U87-ST8SIA3 and U87-shST8SIA3 (p = 0.018) 
and between U87-shcontrol and U87-shST8SIA3 (p = 0.041) but not between U87-ST8SIA3 and 
U87-shcontrol (p = 0.293). Moreover, the diameter of spheres was significantly larger for 
U87-ST8SIA3 (165.9 μm) than for U87-shcontrol (118.7 μm) and U87-shST8SIA3 (99.0 μm) (Figure 
3B). These differences were statistically significant between U87-ST8SIA3 and U87-shST8SIA3 (p = 
0.001) and between U87-ST8SIA3 and U87-shcontrol (p = 0.001) but not between U87-shcontrol and 
U87-shST8SIA3 (p = 0.334). These results indicate that cells overexpressing ST8SIA3 gain clonogenic 
properties and increase their self-renewal and proliferation rate. 
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Figure 2. ST8SIA3 modulates in vitro cell death, proliferation, and migration. (A)(F) Colorimetric 
MTT assay (3-(4,5-dimethylthiazol-2yl)-diphenyl tetrazolium bromide) was performed to compare 
cell viability (n = 5 for each cell line). (B)(G) DNA fragmentation (sub/G1) was determined by flow 
cytometry of propidium-iodide-stained nuclei. Data are expressed as mean ± SEM deduced from five 
independent experiments. (C)(H) Immunofluorescence staining of the proliferation marker Ki67 
(red) in ST8SIA3, shcontrol, and shST8SIA3 cell lines. Cell nuclei are counterstained in blue. Scale bar 
= 50 μm. (D)(I) Quantification of cell migration using the transwell assay determined by the optical 
density of SDS-solubilized crystal violet. The mean + SEM values of four independent experiments, 
each performed in duplicate, are shown. (E)(J) Representative phase contrast images of migrating 
cells. Scale bar = 50 μm. Non-parametric Wilcoxon-Mann-Whitney test shows * p < 0.05, ** p < 0.01, 
and *** p < 0.001. ns: non-significant. 
Then, to determine whether the ST8SIA3 expression level could influence tumorigenicity, we 
performed stereotactic orthotopic intracranial injections of U87-MG, U87-ST8SIA3, and 
U87-shST8SIA3 cells. Expression of A2B5 was analyzed by flow cytometry immediately prior to 
injection. At the end of the experiment, extracted brains were macroscopically and microscopically 
analyzed for the presence of a tumor and its histological characterization. Interestingly, ST8SIA3 
overexpression shortened the overall survival and decreased 1.3-fold the median survival from 42.5 
days (range 36–45) for U87-MG to 32 days (range 23–45) for U87-ST8SIA3-tumor-bearing mice (p < 
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0.05) (Figure 3C). Conversely, a significant improvement of median survival was measured for 
U87-shST8SIA3-bearing mice of 72 days (range 69–75) compared to 42.5 days in U87-MG-ones (p < 
0.05), and as expected, median survival was higher when compared to U87-ST8SIA3 mice (32 days, p 
= 0.02). It is worth noting that in the U87-shST8SIA3 group, only two out of eight mice developed a 
tumor. The data unambiguously demonstrate that in vivo, the A2B5 expression level negatively 
correlates with overall survival. Histologically, tumors did not differ between the three groups of 
mice (Figure 3D). They were dense and mostly circumscribed. However, a clear difference was 
revealed by cleaved caspase 3 immunohistochemistry. The U87-shST8SIA3 tumors showed 
significant higher staining as compared to U87-MG or U87-ST8SIA3 tumors (Figure 3D). In addition, 
U87-shST8SIA3 tumors demonstrated a lower Ki67 proliferation index (30% to 40%) in comparison 
to U87-MG (around 80%) or U87-ST8SIA3 (more than 90%) tumors (Figure 3D). 
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Figure 3. ST8SIA3 enhances in vitro clonogenicity and in vivo tumorigenicity. (A) Self-renewal 
capacity was evaluated by limiting dilution assay in 96-well plates. Box plots show the percentage of 
spheres formed after 8 days of culture for U87-shcontrol, U87-ST8SIA3, and U87-shST8SIA3 [B] cell 
lines. (B) Mean diameter of spheres recorded for U87-shcontrol, U87-ST8SIA3, and U87-shST8SIA3 
[B] after 8 days of culture. Non-parametric Wilcoxon–Mann–Whitney test shows * p < 0.05 and *** p < 
0.001. ns: non-significant. The lower and upper edges of each box represent the first and third 
quartiles, respectively, while the horizontal line within the box indicates the median. The vertical 
length of the box represents the interquartile range (IQR). The most extreme sample values (within a 
distance of 1.5 IQR from the median) are the endpoints of the extending lines. (C) Kaplan–Meier 
survival plot of mice intracerebrally grafted with U87-MG, U87-ST8SIA3, or U87-shST8SIA3 [B] cells. 
Time is expressed in days since time of cell graft. Groups were compared using the Log-rank test. 
The table recaps the percentage of A2B5+ cells before injection, number of brains analyzed, and 
median survival of mice. (D) Representative hematoxylin–eosin (HE), cleaved-caspase 3, and Ki67 
staining of tumors obtained after U87-MG, U87-ST8SIA3, or U87-shST8SIA3 [B] orthotopic injections. 
Scale bar: 100 μm. 
2.4. Suppression of A2B5 Immunoreactivity in High-A2b5-Expressing Cells Induces a Decrease in Cell 
Proliferation, Migration, and Clonogenicity 
As high-A2B5-expressing cells, we used GBM CSCs developed in our laboratory [21]. To 
determine whether A2B5 removal could reverse the stem-like cell phenotype, we silenced ST8SIA3 
in four GBM CSCs: GBM6, GBM9, GBM27, and GBM40. After several infection trials with the 
shST8SIA3 in these four cell lines, we succeeded in producing GBM9-shST8SIA3 spheres with 
undetectable A2B5 immunoreactivity as compared to native GBM9 and GBM9-shcontrol cells 
(Supplementary Figure S1A). However, GBM9-shST8SIA3 culture could not be maintained over 
time, and self-renewal stopped after three passages. Assays performed on these GBM9-shST8SIA3 
cells revealed their drastically impaired migration ability compared to GBM9-shcontrol 
(Supplementary Figure S1B). In GBM6, 27, and 40, ST8SIA3 silencing invariably led to cell death, 
strongly suggesting that A2B5 is necessary to maintain cell growth.  
As an alternative to ST8SIA3 silencing, we decreased A2B5 expression at the surface of the high- 
A2B5-expressing cells by using the hydrolase neuraminidase, which removes α-2,8 bonds [9]. A 
dose–response cytotoxicity assay of neuraminidase (10−4 to 1 U/mL) was conducted for 72 h on 
GBM6, GBM9, GBM27, and GBM40 CSC lines (Figure 4 and Supplementary Figure S2). The enzyme 
concentrations to reduce viability by 50% (EC50) were determined for each cell line. The EC50 values 
were 0.56 U/mL for GBM9 (Figure 4A), 0.98 U/mL for GBM6, 0.47 U/mL for GBM27, and 0.96 U/mL 
for GBM40 (Supplementary Figure S2A–C). Neuraminidase strongly decreased A2B5 expression in 
GBM9 from 48 h to 72 h of treatment (Figure 4B). In GBM9 cells cultured as 3D spheroids, 
concentrations of neuraminidase at 1 and 2 U/mL deeply decreased cell viability (Figure 4C) and 
significantly reduced (by 50%) spheroid size as compared with the control (Figure 4D,E). The same 
dose effects and time effects on spheroid viability and volumes were obtained using spheroids 
produced from GBM6, GBM27, and GBM40 cells (Supplementary Figure S2D–I). 
Finally, inhibition of cell migration by neuraminidase was assessed in GBM CSCs. In GBM9, a 
statistically significant dose effect was detected even at low concentration (0.125 U/mL) (Figure 
4F,G). GBM6, GBM27, and GBM40 cell migration was also strongly reduced in presence of 
neuraminidase (Supplementary Figure S2J–L). In a 7-day subsphere-forming assay, neuraminidase 
at the EC50 concentration significantly impaired the formation of spheres (74%) when compared 
with a non-treated GBM9 cell line (86%, p < 0.05, Figure 4H), the high clonogenicity ability of which 
has been previously described [21]. Similar observations were made for GBM6, GBM27, and GBM40 
(Supplementary Figure S2M–O). U251-MG cells were used to compare shST8SIA3 and 
neuraminidase effects (Supplementary Figure S3). 
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Figure 4. Suppression of A2B5 immunoreactivity in high-A2B5-expressing cells induces a decrease in 
cell proliferation, migration, and clonogenicity. (A) A dose–response cytotoxicity assay of 
neuraminidase (10−4 to 1 U/mL) was conducted for 72 h to assess the viability of GBM9 cells grown as 
a 2D monolayer (n = 3). (B) A2B5 staining (in red) on the GBM9 sphere control or that treated with 0.5 
U/mL neuraminidase (EC50) for 48 and 72 h. (C) A dose-response cytotoxicity assay of 
neuraminidase (0 to 2 U/mL) was conducted for 7 days to assess the viability of GBM9 cells grown as 
3D spheroids (n = 3). (D) The GBM9 spheroid area was measured during the 7 days after 
neuraminidase treatment and normalized to Day 0. (E) Representative phase contrast images at Days 
0, 3, 5, and 7 of the control and treated GBM9 spheroids. (F) Quantification of GBM9 cell migration 
using the transwell assay after neuraminidase treatment at 0.125 and 0.5 U/mL (EC50) for 6 h. The 
mean + SEM values of four independent experiments, each performed in duplicate, are shown. (G) 
Representative phase contrast images of control and treated migrating GBM9 cells. Scale bar = 50 μm. 
(H) Self-renewal capacity was evaluated by limiting dilution assay in 96-well plates. The scatter plot 
shows the percentage of spheres formed after 8 days of culture of GBM9 cells treated or not with 0.5 
U/mL neuraminidase (EC50). Non-parametric Wilcoxon-Mann-Whitney test shows * p < 0.05, ** p < 
0.01. 
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2.5. Neuraminidase Effects in Human GBM Explants 
To determine whether fresh human GBM tissue could respond to neuraminidase as shown 
previously in GBM cell models, we performed explant cultures. First, we analyzed the effect of 
neuraminidase at 1 U/mL for 72 h. As shown in Figure 5A, after 72 h of treatment, A2B5 expression 
was lost in neuraminidase-treated explants. A2B5 removal decreased proliferation as shown by the 
Ki67 expression. By using time-lapse video microscopy, we tracked cell migration in the explants 
(Supplementary Figure S5, Videos 1,2). We followed the behavior of cells radially migrating from the 
core. At early stages of neuraminidase treatment, cellular extensions of migrating cells were 
retracting, whereas in control conditions, extensions stayed intact and continue to grow (see arrows, 
Figure 5B). We recorded the distances of migration of cells from the explant core during those 72 h, 
and neuraminidase treatment significantly reduced migration (Figure 5C,D). Altogether these 
results confirmed in human GBM tissues that neuraminidase treatment leads to a decrease in cell 
proliferation and migration.  
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Figure 5. Neuraminidase affects the migration of human GBM explants. (A) Phase-contrast images 
and immunofluorescent double-staining of A2B5 (in red) and Ki67 (in green) of control and 72 h 
treated (1 U/mL neuraminidase) explants. Cell nuclei are counterstained in blue. Scale bar = 50 μm. 
(B) Using time-lapse video microscopy at regular intervals, cells migrating radially from explants in 
basic conditions or with 1 U/mL neuraminidase were accurately observed for 72 h. Arrows allow us 
to follow the migration of some cells. Scale bar = 50 μm. (C) Representative phase contrast images 
taken over time of control and treated (1 U/mL neuraminidase) explants. For each explant, the central 
red circle allows us to visualize the explant’s core, while the outer red line shows the cell migration 
area. Scale bar = 100 μm. (D) The distance of migrating cells from the explant’s core was quantified in 
basic conditions or with 1 U/mL neuraminidase (n = 3 experiments). Non-parametric Wilcoxon–
Mann–Whitney test shows * p < 0.05 and ** p < 0.01. ns: non-significant. 
3. Discussion 
Our interest in GBM, gliomagenesis, and CSCs brought us to focus on sialogangliosides 
recognized by the monoclonal antibody A2B5. Experimental evidence strongly suggests that 
A2B5-positive cells isolated from GBM represent GBM initiating cells [8,14,15,21]. An open question 
was whether these cell surface sialogangliosides, beside their interest as markers, play an active role 
in influencing GBM cell properties. To answer this question, we used two strategies: overexpressing 
versus suppressing the synthesis of the A2B5 epitope by manipulating the key enzyme ST8SIA3 and 
neuraminidase treatment which abrogates the cell surface A2B5 epitope.  
Introducing the ST8SIA3 coding sequence into low- and mild-level A2B5-expressing GBM cell 
lines resulted in a huge increase of A2B5 immunoreactivity and showed that the A2B5 
immunoreactivity level was positively correlated with ST8SIA3 expression. Consequently, deep 
changes in cell behavior were recorded for proliferation and migration abilities. Moreover, we 
showed that U87-ST8SIA3 cells acquired clonogenic potential and were more tumorigenic in vivo. In 
contrast, when ST8SIA3 silencing was performed in these cells, they lost their ability to migrate in 
vitro and were less tumorigenic in vivo. A strong indication of a functional role of A2B5-bearing 
gangliosides in CSC came from the observation that ST8SIA3 silencing in high-A2B5-expressing CSC 
lines GBM6, GBM9, GBM27, and GBM40 prevented their maintenance in culture, likely by impairing 
cell growth and proliferation. To confirm this hypothesis, we reduced the A2B5 cell surface level in 
these GBM CSCs by using neuraminidase, a hydrolase which cleaves alpha 2–8 neuraminic acid 
bonds. The removal of the A2B5 epitope by neuraminidase in CSCs decreased survival, migration, 
and clonogenicity. It is worth noting that on U251-MG cells, similar effects were recorded with 
neuraminidase or shST8SIA3, confirming that these two approaches lead to a decrease in A2B5 
immunoreactivity. Moreover, we also demonstrated that in an ex vivo human GBM model, A2B5 
removal by neuraminidase blocked cell migration at early time points. Taken together, our results 
support a major role of the A2B5 epitope in cellular growth, proliferation, and migration.  
Furthermore, we showed that A2B5 is involved in tumor initiation. By transplanting 
U87-ST8SIA3 and U87-shST8SIA3, we gained insight about the role of A2B5 in tumor initiation and 
growth. U87-ST8SIA3 cells developed tumors faster than U87-MG. Therefore, by increasing A2B5 
expression, tumor grafting was more efficient. Besides this, only two out of eight 
U87-shST8SIA3-injected mice developed a tumor, and in these mice, tumor development was 
postponed, probably due to residual A2B5-positive cells in the grafted cell suspension. These results 
are in line with those observed with the GD3 ganglioside, which is the main precursor of GT3 that 
carries the A2B5 epitope. Introduction of the cDNA of GD3 synthase (also called ST8SIA1) into the 
U251-MG cell line induces high levels of GD3 and GD2 on the cell surface, leading to an increase of 
invasion and mobility [7]. Moreover, Yeh et al. showed that GD3 and GD3 synthase are key drivers 
of GBM stem cells and tumorigenicity [6]. Importantly, GD3 is also required for neurogenesis and 
long-term maintenance of neural stem cells in the postnatal mouse brain [22]. However, in these 
studies, the authors did not search for A2B5 expression. These observations could therefore be 
associated either to GD3 or to A2B5 expression. 
The mechanisms by which the A2B5 epitope could act on cell proliferation, migration, 
clonogenicity, and tumorigenicity are worth exploring. Ganglioside head groups, protruding 
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toward the extracellular space, significantly contribute to the cell glycocalyx and are major 
determinants of the features of the cell surface. In particular, they modulate complex interactions 
with other molecules sitting on the same cellular membrane (cis interactions) or soluble molecules 
present in the extracellular environment or with molecules associated with the surface of other cells 
(trans interactions) (reviewed in [2,23]). It is thus conceivable that the effects of A2B5 gangliosides 
are exerted by modulating the activity of receptors and their following signaling cascades [24]. 
Besides this, the A2B5 epitope, like other gangliosides, represents an attractive therapeutic 
target. GD2- and GD3-targeting immunotherapies are currently under clinical or preclinical 
investigations in several solid tumors [25] (reviewed in [24]). Several approaches have been 
proposed to target gangliosides, including cancer vaccination, monoclonal antibodies, and CAR-T 
(Chimeric Antigen Receptor T) cells. In GBM cells it has been reported that adjuvant monoclonal 
antibody 8B6, which targets O-acetyl GD2, impairs temozolomide resistance driven by glioma CSCs 
[5]. Of particular interest, the potent anti-tumor efficacy of anti-GD2 CAR T cells has recently been 
reported in mouse models of H3K27M+ midline gliomas, a highly infiltrative and fatal glioma [26]. 
In addition of immunotherapy targeting cell surface gangliosides, another attractive therapeutic 
approach, relies on the potential use of intracellular antibodies to prevent the translocation of the 
sialyltransferase from the endoplasmic reticulum to the Golgi apparatus. This approach has been 
successfully used in experimental models targeting ST8SiaII and ST8SiaIV in order to inhibit 
polysialylation of NCAM (Neural Cell Adhesion Molecule) in rhabdomyosarcoma tumor cells [27]. 
Furthermore, it is known that sialic acids are responsible for an immune-suppressive environment. It 
has been shown that the inhibition of sialylation through sialic acid mimetic drugs induced CD8+ 
T-cell-mediated killing of tumor cells in various murine tumor models [28]. The strong expression of 
highly sialylated gangliosides such as those recognized by the A2B5 antibody might explain to some 
extent the failure of clinical trials targeting immune checkpoint inhibitors in GBM (reviewed in [29]). 
Altogether it is likely that targeting A2B5 in GBM cell lines is a promising therapeutic approach. 
Such a treatment might not only act on tumor cells but might also lead to a more permissive immune 
environment. This will pave the way for efficient treatments that combine sialic acid targeting and 
immune checkpoint inhibitors in GBM. 
4. Materials and Methods  
4.1. Cell Lines and Reagents 
U251-MG and U87-MG cell lines (American Type Culture Collection, Manassas, VA, USA) were 
cultured as an adherent monolayer in Dulbecco’s modified Eagle’s medium (DMEM, Life 
Technologies, Courtaboeuf, France) supplemented with 10% heat-inactivated fetal calf serum (FCS, 
Life Technologies), 50 U/mL penicillin, and 50 μg/mL streptomycin (Life Technologies) at 37 °C in a 
humidified atmosphere of 5% CO2 and 95% air. Confirmation of U251-MG and U87-MG identity was 
performed by LGC standards (Teddington, Middlesex, UK). GBM6, GBM9, GBM27, and GBM40 
CSC lines, established at our laboratory on the basis of A2B5 expression from different human GBM 
tumor samples, exhibited features reminiscent of the clinical characteristics of the original tumors. 
They were maintained in culture as floating spheres in serum-free medium supplemented with EGF 
(Epidermal Growth Factor) and bFGF (basic Fibroblast Growth Factor) as previously described 
[14,21]. In these cell lines, the A2B5 level recorded by flow cytometry was usually 80%–90% [14]. All 
cells were tested monthly for the absence of mycoplasma. Neuraminidase (sialidase) from 
Clostridium perfringens was purchased from Sigma-Aldrich. It was dissolved at 50 U/mL in sterile 
water and stored at 4 °C until use. For neuraminidase treatment experiments, cells were grown 
either as monolayers (for CSC, on 10 μg/mL poly-DL-ornithine (Sigma-Aldrich, coated plates, 
Saint-Quentin Fallavier, France) or as spheres. Cells and spheres were treated at their EC50 
(U251-MG and U87-MG: 0.091 U/mL; GBM6: 0.98 U/mL; GBM9: 0.56 U/mL; GBM27: 0.47 U/mL and 
GBM40: 0.96 U/mL; Figure 4A and Supplementary Figure S2A–C). 
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4.2. Manipulation of ST8SIA3 Expression 
4.2.1. Overexpression of ST8SIA3 
The coding region of ST8SIA3 (Unigene ID: Hs.23172) was subcloned into the lentiviral vector 
pRRLSIN.cPPT.PGK-GFP.WPRE (referred to as pRRL, kindly provided by Trono, University of 
Geneva, Geneva, Switzerland). This was used for the generation of stable ST8SIA3-expressing 
U251-MG and U87-MG cell lines using the conventional protocol. Lentiviral particle preparation and 
infection of the human cells with viral particles were performed according to Mathieu et al. [30]. The 
expression level of ST8SIA3 was monitored by RT-qPCR and/or immunofluorescence. 
4.2.2. Down-Regulation of ST8SIA3: SHST8SIA3 
In our experiments, the ST8SIA3 shRNA expression cassette consisted of a 29 bp 
target-gene-specific sequence (cacacttcagcaactgtgaccaggacatt (A) or gctgctggccgctcaatggaccgatttcc (B) 
or aacggctgagcacaggtattcttatgtac (C) or ctctgtcacactgtgcctaagaactccaa (D)), a 7 bp loop, and another 
29 bp reverse complementary sequence, all under human U6 promoter in a pGFP-C-shLenti vector 
also expressing enhanced green fluorescent protein (GFP) under CMV (cytomegalovirus) promoter 
(OriGene Technologies, Rockville, MD, USA). The preparation of shST8SIA3 lentiviral particules 
was performed according to instructions from OriGene Technologies. In brief, HEK293T cells were 
co-transfected with pGFP-C-shLenti together with the packaging plasmid and MEGA-TRAN. 
Lentivirus-containing supernatants were harvested, filtered through 0.22 μm cellulose acetate filters 
(Merck KGaA, Darmstadt, Germany), aliquoted, and stored at −80 °C until use. For lentiviral 
infection, the culture medium was removed when U251-MG and U87-MG cells were at 80% 
confluence. They were washed with PBS and treated with the virus-containing medium combined 
with 5 μg/mL polybrene (Sigma-Aldrich). After 72 hours of transduction, 0.2 μg/mL puromycin (Life 
Technologies) was added to the medium for stable cell line selection. The lentiviral vector carrying a 
29 mer scrambled sequence cassette was used as a negative control (OriGene Technologies) 
(Supplementary Figure S4). For shST8SIA3-GBM6, -GBM9, -GBM27, and -GBM40 production, cells 
were seeded beforehand on 10 μg/mL poly-DL-ornithin with serum-free medium. Under these 
conditions, they were able to adhere to the plastic without differentiating [14]. At 80% confluence, 
infection was performed as explained above. 
4.3. Immunostainings 
U251-MG and U87-MG cell lines were grown as a monolayer on glass coverslips in 24-well 
plates in DMEM with 10% FCS. For GBM CSCs, immunofluorescence experiments were performed 
on 8-day-old spheres or on cells cultured on poly-DL-ornithin as explained above. Primary 
antibodies A2B5 (mouse IgM, clone 105, 1/1000, kindly provided by G. Rougon, Marseille, France), 
anti-ST8SIA3 (rabbit IgG, 1/1000, Sigma-Aldrich), and anti-Ki67 (mouse IgG, clone Mib1, Dako, Les 
Ulis, France) were incubated for 1 h at room temperature. Fluorochrome-conjugated secondary 
antibodies Alexa fluor 568 anti-mouse IgM, Alexa fluor 488 anti-rabbit IgG, Alexa fluor 568 
anti-mouse IgG, or Alexa fluor 568 anti-goat IgG (Molecular Probes, Eugene, OR, USA) were 
incubated at 2 μg/mL for 1 h at room temperature together with Hoechst 33342. All the images were 
obtained using a Zeiss AXIO-Observer Z1 microscope (Carl Zeiss SAS, Marly-le-Roi, France). 
Conventional immunohistochemistry for cleaved caspase-3 (C92-605 clone, 1/500, BD Biosciences, 
Franklin Lake, NJ, USA ) and Ki67 (30-9 clone, Ventana Medical Systems, Illkirch, France) was 
performed using the Benchmark XT automate (Ventana Medical Systems) according to the 
manufacturer’s instructions. Sections without primary antibody served as a negative control. 
4.4. Flow Cytometry 
Flow cytometry was performed using FACS Calibur (BD Biosciences) on dissociated cells to 
quantify the number of cells expressing A2B5 (APC (Allophycocyanin)-labelled IgM, clone 105, 
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Miltenyi Biotec, Bergisch Gladbach, Germany) using a previously described standard procedure 
[14,21]. Data were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). 
4.5. Protein Extraction and Western Blotting  
Experiments were performed as previously described [31] using the following primary 
antibodies: anti-ST8SIA3 (rabbit IgG, 1/1000, Sigma-Aldrich) or anti-β-actin (mouse IgG, 1/5000, 
clone AC-15, Merck KGaA) as an internal loading control.  
4.6. Viability/Cytotoxicity Assay 
For two-dimensional (2D) experiments, cell viability was measured using the colorimetric MTT 
assay (3-(4,5-dimethylthiazol-2yl)-diphenyl tetrazolium bromide, Sigma-Aldrich) as previously 
described [32]. For 3D experiments, cell viability was assessed by resazurin reduction (alamarblue, 
Thermo Fisher Scientific, Vellebon-sur-Yvette, France) after 7 days of treatment as previously 
described [33].  
4.7. DNA Fragmentation 
Fluorescence-activated cell sorting (FACSCalibur) analysis of the DNA fragmentation of 
propidium-iodide-stained nuclei was performed as described in [34]. 
4.8. In Vitro Migration Assay  
A total of 50,000 cells was seeded in serum-free DMEM on the filter membranes of 8 μm 
transwell migration chambers (Corning Inc., Amsterdam, The Netherlands). DMEM with 10% FCS 
was added to the wells under the filter and cells were allowed to migrate for 6 h. Transmigrated cells 
were fixed in 4% paraformaldehyde and stained with 0.4% crystal violet, and membranes were 
photographed (Carl Zeiss SAS™). For quantification, cells were counted or crystal violet was 
solubilized in SDS 1% and absorbance was measured at 550 nm using an Elx800 microplate reader 
(Bio-Tek, Colmar, France). 
4.9. Limiting Dilution Assay  
The U87-MG cell line was plated in limiting dilution conditions in 96-well plates. Clonal 
frequency was quantified at Day 8. At the same time, the diameter of spheres was recorded as 
previously described [14,21]. For GBM CSCs, the number of spheres was reported relative to the 
total number of cells seeded to evaluate the sphere formation property after 8 days of neuraminidase 
treatment. 
4.10. Reverse Transcription, Real-Time Quantitative PCR Analysis (RT-qPCR) 
Total RNA extraction and gene expression analysis were performed as previously described 
[32]. Ribosomal 18S and glyceraldehyde-3-phosphate-deshydrogenase (GAPDH) were used as 
reference genes. Forward and reverse primers for each gene are listed below: 18S: 5’- 
CTACCACATCCAAGGAAGGCA-3', 5'-TTTTTCGTCAACTACCTCCCCG-3'; GAPDH: 
5'-CAAATTCCATGGCACCGTC-3', 5'-CCCACTTGATTTTGGAGGGA-3'; and ST8SIA3: 
5’-TCCCTGCATTTTTCTTCCAC-3’, 5’-ACGGCCAAAATCCATACAAGC-3’. The PCR conditions 
were 5 min at 95 °C followed by 45 cycles of 15 s at 95 °C and 30 s at 65 °C. The relative expression of 
the target gene transcript was calculated as previously described [35] using human brain total RNA 
as the control (Agilent Technologies™, Les Ulis, France). Measurements were performed in 
triplicate. Results are expressed in arbitrary units (A.U.) as a percentage of control RNA. 
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4.11. Intracranial Injections  
All experimental procedures and animal care were carried out in accordance with the 
guidelines of the French Government, reviewed and approved by the Regional Institutional 
Committee for Ethics on Animal Experiments under the authorization number 04633.01. 
Six-week-old athymic female nude mice (Envigo) were anesthetized, and 50,000 cells of U87-MG (n = 
18), U87-ST8SIA3 (n = 18), and U87-shST8SIA3 [B] (n = 10) were stereotactically injected into the 
corpus callosum (1 mm anterior to bregma, −1 mm lateral, and −2 mm deep in the cortex surface) as 
previously described [14]. The body weight and clinical status of mice were recorded every 2 days. 
Mice were euthanatized when they exhibited more than a 20% reduction from their initial body 
weight or significant neurological or motor deficit. Brains were immediately extracted, fixed in 
formalin, paraffin embedded, sectioned at 4 μm thickness, and processed to validate tumor 
development and for standard histology (hematoxylin-eosin staining). 
4.12. Explant Cultures of Human GBM Tissue 
Primary human GBM samples (n = 5) were collected at Assistance Publique-Hôpitaux de 
Marseille (AP-HM) after surgery and placed in Hank's Balanced Salt Solution. Tissues were 
mechanically cut into 300 μm pieces and plated in 24-well plates (BD Biosciences) on coverslips 
precoated with poly-L-lysine (10 mg/mL; Sigma-Aldrich). Serum-free medium was supplemented 
with 0.4% methylcellulose (Sigma-Aldrich). Explant cultures were then incubated at 37 °C in a 
humidified atmosphere of 5% CO2 and 95% air. After 7 days of culture, explants were treated with 1 
U/mL neuraminidase. Immunofluorescence was performed 72 h later. 
Time-lapse video microscopy was used to analyze explant migration. After the 7 days of 
culture, explants were treated or not with 1 u/mL of neuraminidase and were transferred to a Zeiss 
AXIO-Observer Z1 microscope (Carl Zeiss SAS) equipped with a CO2 chamber and maintained at 37 
°C. Images of the explants were captured every 10 min for periods of 72 h using a 5× objective in 
order to obtain a quantitative analysis of the cell migration. Quantifications of the area core and the 
total area of explants were performed using ImageJ software (National Institutes of Health). 
Quantifications are represented by the (total area)/(core area) ratio and data were standardized 
using the H0 ratio. Data from three distinct GBM samples are presented and expressed as mean ± 
SEM. 
4.13. Statistical Analyses 
The non-parametric Wilcoxon-Mann-Whitney test was conducted using XLSTAT 2013 software 
(Addinsoft, Paris, France) to analyze cell migration and proliferation rates, flow cytometry, DNA 
fragmentation, and clonogenicity. Overall survival curves of intracranial xenografted mice were 
obtained according to the Kaplan-Meier method and compared using the Log-rank test using 
GraphPad Prism4 software (GraphPad, Inc., San Diego, CA, USA). All statistical tests were 
two-sided, and the threshold for statistical significance was p < 0.05. Significances are denoted as 
follows: *** p < 0.001, ** p < 0.01, * p < 0.05.  
5. Conclusions 
In conclusion, our findings prove the crucial role of the A2B5 epitope in the promotion of 
proliferation, migration, clonogenicity, and tumorigenesis, indicating that it is an attractive 
therapeutic target for glioblastomas. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: ST8SIA3 
silencing in high-A2B5-expressing cells leads to cell death. Figure S2: Suppression of A2B5 immunoreactivity in 
GBM6, GBM27, and GBM40 by neuraminidase impairs cell proliferation, migration, and clonogenicity. Figure 
S3: Suppression of A2B5 immunoreactivity in U251-MG cells by neuraminidase induces decrease in cell 
proliferation, migration, and clonogenicity. Figure S4: Western blot analysis of ST8SIA3 in shST8SIA3 cell 
clones. Figure S5: Time-lapse of the migration of GBM explants over 24 h, untreated (Video 1) or treated with 
neuraminidase (1 U/mL) (Video 2). 
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